Homepage > Company > Media > Pharma News > 2019 > France has no plans to legalize cannabis for recreational use: minister

France has no plans to legalize cannabis for recreational use: minister

PARIS (Reuters) - France will not legalize the recreational use of cannabis but could consider authorizing its medical use, Transport Minister Elisabeth Borne said on Thursday.

“The position of the French state is clear. We are against legalizing cannabis for recreational use. There is an ongoing discussion about a medical use,” Borne told LCI television.

Borne’s comments follow publication of a report on Thursday by French think-tank the Conseil d’Analyse Economique recommending legalizing cannabis for recreational use in France.

Several countries, including Germany, Italy and Denmark, already allow the prescription of medical cannabis and last year Canada became the second country in the world to fully legalize marijuana.

In France, GreenLeaf, a French hemp-based and cannabis healthcare company, recently said it had agreed to be bought by rival EMMAC Life Sciences Ltd, as the legal use of cannabis for medicinal purposes grows further.

JUNE 20, 2019

https://www.reuters.com/

Read also

Pfizer touts Tukysa in front-line breast cancer after Phase III victory

Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage trial in breast cancer.

Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer

Telomir Pharmaceuticals, Inc., a $54 million market cap biotech company whose stock has declined 11% in the past week

Компания 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Gene Therapy Protects Kidneys in Preclinical Model of Type 1 Diabetes

One in three people with type one diabetes will develop kidney damage during their lifetime, which can develop silently over many years, often going undetected until it becomes severe.